Walleye Capital’s Legend Biotech LEGN Stock Holding History

Walleye Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Sell	63,400 -18,400	-22%	-$351K	﹤0.01%	1945
2025 Q4	$1.78M	Buy	81,800 +61,300	+299%	+$1.76M	0.01%	1970
2025 Q3	$669K	Buy	20,500 +7,100	+53%	+$262K	﹤0.01%	2385
2025 Q2	$476K	Buy	13,400 +3,000	+29%	+$97.2K	﹤0.01%	2682
2025 Q1	$353K	Sell	10,400 -8,100	-44%	-$290K	﹤0.01%	2832
2024 Q4	$602K	Sell	18,500 -600	-3%	-$24.9K	﹤0.01%	2842
2024 Q3	$931K	Sell	19,100 -57,700	-75%	-$3.07M	﹤0.01%	2726
2024 Q2	$3.4M	Buy	76,800 +72,800	+1,820%	+$3.36M	0.01%	1603
2024 Q1	$224K	Buy	4,000 +3,000	+300%	+$181K	﹤0.01%	3900
2023 Q4	$60.2K	Sell	1,000 -2,800	-74%	-$177K	﹤0.01%	4244
2023 Q3	$255K	Buy	+3,800	New	+$264K	﹤0.01%	3361
2022 Q4	–	Sell	-23,400	Closed	-$955K	–	3434
2022 Q3	$955K	Buy	+23,400	New	+$1.1M	0.02%	1016

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FBIL

First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Walleye Capital's LEGN Position: Q1 2026 in Review

Walleye Capital reduced its Legend Biotech (LEGN) stake by 21% in Q1 2026, selling an estimated $1.22M and leaving 235,415 shares worth $4.26M. The position accounts for 0.02% of the portfolio, ranked #903.

Walleye Capital first reported a position in LEGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $6.51M in Q4 2025. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

Walleye Capital held 235,415 shares of Legend Biotech worth $4.26M as of Q1 2026.
Walleye Capital sold 64,048 Legend Biotech shares in Q1 2026, an estimated $1.22M.
Legend Biotech made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #903 holding.
Walleye Capital first reported a position in Legend Biotech in Q1 2024 and has held it in 9 quarters since.
Walleye Capital's Legend Biotech position peaked at $6.51M in Q4 2025.
189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.